Clinical trials
Primary CNS Lymphoma clinical trials
Below are recruiting primary cns lymphoma clinical trials, each written for real people, not researchers. We’re tracking 74 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06737250RecruitingPhase 2
Testing a new drug combo for relapsed brain lymphoma
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
BusanAges 19–80 - NCT05036564Recruiting
Biopsy and spinal fluid testing for newly diagnosed brain lymphoma
This study uses brain biopsy and spinal fluid (lumbar puncture) tests to better diagnose and understand how well treatments may work for certain lymphomas in the brain. It may help doctors match the right therapy by studying what the disease looks like in the body and brain.
Milan, Italy/LombardyAges 18 years+ - NCT04627753RecruitingPhase 2
Lenalidomide plus rituximab to prevent brain lymphoma return
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
SeoulAges 19 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Los Angeles, CaliforniaAges Up to 25 years - NCT06343311RecruitingPhase 1/Phase 2
T-cell therapy for adults with relapsed or refractory B-cell lymphoma
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Sacramento, CaliforniaAges 18 years+ - NCT07098364RecruitingPhase 1/Phase 2
ST-067 with CAR T-cell therapy for large B-cell lymphoma
This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.
Seattle, WashingtonAges 18 years+ - NCT05828628Recruiting
Study tests imaging and tissue markers in brain lymphoma
This study looks at how primary central nervous system (CNS) lymphoma can be identified and tracked using scans and molecular (tissue/biomarker) tests. It may help doctors better understand your disease and choose the best next steps.
SuttonAges 18 years+ - NCT07191431Recruiting
Study of drug combo for returning brain lymphoma
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT07014943RecruitingPhase 2
High-dose chemo and stem cell transplant for brain lymphoma
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
Chengdu, SichuanAges 16–70 - NCT05600660RecruitingPhase 2
Testing a new combo treatment for newly diagnosed brain lymphoma
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
Hanzhou, ZhejiangAges 18–75 - NCT06556199RecruitingPhase 1/Phase 2
Study of selinexor combo for returning brain lymphoma
This trial tests a new combination of drugs (selinexor, temozolomide, and an immunotherapy) for people whose primary central nervous system lymphoma has come back or stopped responding to previous treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hanzhou, ZhejiangAges 18–75 - NCT07604987RecruitingPhase 2
New Treatment for Brain Lymphoma (R-PMDT)
This trial tests a combination drug treatment called R-PMDT for patients newly diagnosed with a type of lymphoma that starts in the brain (PCNSL). The goal is to see if this regimen can help control the cancer and improve outcomes.
TianjinAges 18 years+ - NCT07283822RecruitingPhase 2
Pembrolizumab and Ruxolitinib for Lymphoma
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
New York, New YorkAges 18–95 - NCT05098613RecruitingPhase 1
Testing a new immune cell therapy for relapsed B-cell lymphoma
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
Aurora, ColoradoAges 16 years+ - NCT05326243RecruitingPhase 1/Phase 2
CAR-T therapy for hard-to-treat B-cell lymphoma
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
Taipei, TaiwanAges 14 years+ - NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT04186520RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell lymphomas
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
Milwaukee, WisconsinAges 18–80 - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
Boston, MassachusettsAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT07168486Enrolling by invitationPhase 1
CAR T-cells targeting CD19, CD20, and CD22 for lymphoma
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
Baltimore, MarylandAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT07473167RecruitingPhase 1/Phase 2
Study of TC011 for large B-cell lymphoma that has not responded to treatment
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
Seoul, SeoulAges 19 years+
Hear when a new Primary CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary cns lymphoma?
- Yes. Clin2 currently lists 74 recruiting primary cns lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary cns lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary cns lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Primary CNS Lymphoma (PCNSL)
- Primary Central Nervous System (CNS) Lymphoma
- Primary Central Nervous System Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- CNS Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.